TREND: TREatment of degeNerative and Neoplastic Diseases With Rituximab

Sponsor

Probiomed S.A. de C.V. (Industry)

Overall Status

Unknown status

CT.gov ID

NCT01277172

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

4.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of PBO-326 (Rituximab) and Mabthera (Rituximab) in combination with CHOP in previously untreated patients with diffuse B cells Non Hodgkin lymphoma.

Condition or Disease	Intervention/Treatment	Phase
Diffuse Large B Cell Lymphoma	Biological: Rituximab Biological: Rituximab Biological: Rituximab Biological: Rituximab	Phase 2/Phase 3

Detailed Description

At present R-CHOP (Rituximab plus Cyclofosfamide, Doxorrubicine, Vincristine and Prednisone) has became standard of care of patients with B cells Non Hodgkin Lymphoma CD20+.

Study will perform pharmacodynamic (PD) and pharmacokinetic (PK) measurment of a novel Rituximab in comparison with Mabthera and evaluates safety both metabolic as well immunologic.

Study protocolo is designed to provide data on impact of treatment interchange of both study drugs (PBO-326 and Mabthera).

Study Design

Study Type:

Interventional

Anticipated Enrollment :

54 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients

Study Start Date :

Oct 1, 2010

Anticipated Primary Completion Date :

Sep 1, 2011

Anticipated Study Completion Date :

Oct 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group 1 / PBO-326 This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.	Biological: Rituximab 375 mg/m2 IV every 2 weeks for 6 cycles Other Names: Monoclonal Antibody against CD20
Active Comparator: Group 2 / Mabthera This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.	Biological: Rituximab 375 mg/m2 IV every 2 weeks for 6 cycles Other Names: Monoclonal Antibody against CD20
Experimental: Group 3 / PBO-326 This group will be treated six cycles with PBO-326	Biological: Rituximab 375 mg/m2 IV every 2 weeks for 6 cycles Other Names: Monoclonal Antibody against CD20
Active Comparator: Group 4 / Mabthera This group will be treated six cycles with Mabthera	Biological: Rituximab 375 mg/m2 IV every 14 days for 6 cycles Other Names: Monoclonal antibody against CD20

Outcome Measures

Primary Outcome Measures

Basal and final serum CD 20 levels comparison. [Every 14 days for the duration of treatment]
Primary outcome is the depletion of CD20+ B cells. This will be measured every 14 days and comparison will be made basal levels versus visit 2, visit 3, visit 4, visit 5, visit 6, visit 7 and visit 8.

Secondary Outcome Measures

Comparison of safety of PBO-326 versus Mabthera [Every 14 days measurements]
Adverse events will be observed and recorded in relation to acute infusion events (number of cases and severity of hypotension, hipertension, headache, and all cardiovascular events previously reported by Mabthera) as well as long term effects over key hematological cells (number of cases and severity of neutropenia, trombocytopenia, leucopenia) per visit.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Newly diagnosed subjects with a confirmed pathologic diagnosis of diffuse large B cell non-Hodgkin's lymphoma (DLBCL) based on the 2008 World Health Organization classification.
CD20+ lymphoma cells at screening.
18 years of age at screening.
Ann Arbor Stages I-IV at screening.
Any IPI score at screening.
Easten Cooperative Oncology Group (ECOG) performance status (0-2) or Karnofsky scale > 60 at screening.
Left ventricular ejection fraction > 50%.
Willing and able to provide written informed consent prior to performing study procedures.
Women of childbearing potential must use effective contraceptive methods starting from screening and until 12 months following the last infusion.

Exclusion Criteria:

Hodgkin lymphoma.
Any lymphoma other than CD20+ Diffuse Large B Cell Lymphoma (DLBCL).
Immunodeficiency syndrome or Human immunodeficiency virus (HIV) seropositivity .
Active uncontrolled infection (viral, bacterial or fungal infection) requiring systemic therapy at screening and/or at baseline visit.
Function Liver tests >2 x upper normal values.
Positive Hepatitis B surface antigen or antibodies to Hepatitis C.
Any other serious active disease or co-morbid medical condition.
Subjects who, according to the investigator, are likely to be non-compliant or uncooperative during the study.
Pregnant or breast-feeding women or women that intend to get pregnant during study or within 12 months following the last infusion.
Treatment with any investigational drug within 90 days before day 1 of study treatment.